EGFR and pancreatic neoplasm: In pancreatic cancer, CA19-9, a carbohydrate antigen, is known to promote activation of EGFR signaling and induce a pancreatitis phenotype and when combined with KrasG12D resulted in the development of pancreatic cancer (11), demonstrating glycosylation changes are not just biomarkers but can function as drivers of the oncogenic process.